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Conjugation of a short peptide fragment from a bZIP pro- 
tein to an oligoguanidinium tail results in a DNA-binding 
miniprotein that selectively interacts with composite se- 
quences containing the peptide-binding site next to an A/T- 
rich tract. In addition to stabilizing the complex with the 
target DNA, the oligoguanidinium unit also endows the 
conjugate with cell internalization properties. 
 
Transcription Factors (TFs) are specialized proteins that participate 
in the regulation of gene expression by binding to key DNA regula- 
tory sequences,1 and thereby promoting or inhibiting the assembly of 
the transcriptional complex.2 According to this fundamental role, 
alterations in the activity of TFs are at the origin of many diseases, 
including cancer.3 In this context, there has been a great interest in 
the development of synthetic miniproteins that can reproduce the 
DNA recognition properties of natural TFs.4 
It is known that efficient DNA recognition typically involves the 
cooperative action of multiple protein domains,5 and isolated mon- 
omeric modules of TFs usually fail to interact with their DNA tar- 
gets. This complicates the development of minimized synthetic 
versions of natural TFs.6 One of the most successful strategies to 
make miniature DNA binding proteins consists of  combining  the 
DNA binding domain or fragment of a natural TFs with a small 
molecule, such as intercalators or minor groove binders.7 Following 
this approach, our group has shown that linking the basic regions of 
bZIP TFs, or single units of zinc finger DNA binders to distamycin 
or bisbenzamidine derivatives affords conjugates that display high 
affinity for specific DNA sequences of up to nine base pairs.8 On the 
other hand, a major obstacle in translating these synthetic binders to 
a real cellular context derives from their poor cellular uptake. In 
recent years, the discovery of cell-penetrating peptides (CPPs) has 
opened new opportunities for transporting designed cargoes inside 
living cells.9 While most CPPs consist of arginine-rich peptidic se- 
quences, non-peptidic bicyclic guanidinium oligomers have also 
demonstrated good  translocation  properties.10 In  addition to  their 
potential transport applications, qualitative molecular modeling 
suggests that the periodicity of hydrogen bond donors in these oli- 
gomers might fit that of the phosphate backbone in a double strand- 
ed DNA, thus favoring DNA recognition (Figure 1b).11 Therefore, we 
envisioned that these guanidinium oligomers could be used as elec- 
trostatic anchors for the stabilization of the DNA complexes of TF 
fragments that otherwise would not bind to their target site. Indeed, 
many DNA-binding proteins make use of short oligocationic peptide 
tails to increase the thermodynamic stabilization of their complexes 
with the DNA.12 Moreover, we expected that the resulting hybrids 
might be able to cross cell membranes. 
 
 
Fig 1. (a) Oligoguanidines used in this study. (b) Structural proposal 
of the interaction between an oligoguanidine and the DNA; view 
along the DNA axis showing potential hydrogen bonds. (c) Cartoon 
representation of a designed hybrid bound to the DNA. The se- 
quences of the GCN4 basic region (br) and the target peptide (brC) 
are also shown. 
 
Herein, we report the synthesis, DNA binding and cell internaliza- 
tion studies of conjugates between a protein fragment of a bZIP TF, 
and bicyclic oligoguanidiums (Figure 1c). These studies revealed that 
the presence of the guanidinium oligomer not only allows the effi- 
cient DNA recognition by the peptidic unit, but also provides for a 
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sequence selective interaction in the DNA minor groove. In addition, 
we demonstrate that, in contrast to the parent peptide, the oligo- 
guanidinium conjugate is efficiently internalized by cells. 
Our design is based o GCN4, an archetypical bZIP TF that specifical- 
ly   binds   to   AP1   (5’–ATGA(c)TCAT–3’)   or   ATF/CREB   (5’– 
ATGA(c/g)TCAT–3’) sites.13 The DNA contact takes place through 
the basic regions, which comprise ~20 N-terminal residues and fold 
into α-helices only upon binding to their target DNA.14 Isolated basic 
regions are unable to interact with their DNA target site with rea- 
sonable affinity. We synthesized a GCN4 fragment comprising resi- 
dues Asp226 to Gln248 (br).15 This core sequence was extended with 
a cysteine residue at the C-terminus as nucleophilic handle for the 
attachment of the oligoguanidium fragments. 
The peptide brC was synthesized following standard Fmoc solid 
phase peptide synthesis protocols, and purified by HPLC. As electro- 
philic coupling partners we chose the mesylates 1 and 2, featuring 
either tetra- (Gu4) or pentaguanidinium (Gu5) units.16 Conjugation 
between the peptide brC and the oligoguanidinium mesylates was 
performed by heating the corresponding mixtures in phosphate 
buffer (pH 10) at 40 ºC for 14 h. The desired products, brC–Gu4 and 
brC–Gu5, were isolated in moderate yields (45 % and 28%, respec- 
tively), and identified by ESI-MS. As a control, we also synthesized a 
conjugate containing an octaarginine instead of the oligoguanidini- 
ums (brC–R8), obtained by incubating at rt the peptide brC with an 
N-terminal bromoacetylated Gly2-Arg8 peptide (Scheme 1 and ESI). 
 
Aba – DPAALKRARNTEAARRSRARKLQC   –CONH2 
brC 
brC–Gu4 nor brC–Gu5 give rise to retarded EMSA bands (Figure 2, 
panels B1 and C1, and ESI). Remarkably, the oligoarginine control 
brC–R8 induces smeared bands with AP1hs•A/T, indicating the 
formation of a weak 1:1 complex and a number of ill-defined com- 
plexes, possibly arising from non-specific electrostatic interactions 
(Figure 2, panel A2).18 This effect is even more pronounced in the 
case of the mutated oligo AP1hs•mA/T, which gives rise to heavily 
smeared bands in the gel (Figure 2, panel B2). As expected, this 
control conjugate does not show new bands in the presence of the 
mutated DNA mAP1hs•A/T lacking the binding site for the basic 
region. These data, and particularly the sequence selectivity dis- 
played by brC–Gu4 and brC–Gu5, suggest that the oligoguanidine is 
not merely working as an electrostatic anchor, but it might also be 
establishing some sequence-specific interactions, likely through its 
(partial) insertion into the DNA minor groove. Control experiments 
with two oligonucleotides containing one or three G/C-base pairs as 
spacers between the peptide half-site and the A/T-rich region, con- 
firmed the selectivity of the interaction of brC–Gu5 with the target 
site (see ESI). 
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S Fig 2. EMSA  studies  of the  binding of  brC–Gu5   and  brC–R8   to 
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different dsDNA (Lanes 1-3 in all panels correspond to 0, 200 and 
300 nM of the brC conjugate and ≈ 50 nM of each DNA with a small 
fraction (≈ 0.1%) of 32P-labeled oligo for radioactive detection. Sam- 
ples were incubated for 30 min in 18 mM Tris (pH 7.0), 50 mM KCl, 
Scheme 1. Key steps in the synthesis of the conjugates of the basic 
region of GCN4 (brC). Aba stands for p-aminobenzoic acid, and is 
included as a chromophore for spectroscopic monitorization. 
1.2 mM MgCl2, 0.5 mM EDTA, 9% glycerol, 0.11 mg/mL BSA and 
4.2% NP–40 at 20 ºC. AP1hs•A/T: 5'–ACGAACG TCAT • AATTT 
CCTC–3'; mAP1hs•A/T: 5'–ACGAACG CGGC • AATTT CCTC–3', 
hs 
Following the synthesis of the oligoguanidinium and arginine conju- AP1 •mA/T: 5'–ACGAACG TCAT • GGCCG CCTC–3’ (peptide 
gates, we studied their DNA binding properties by electrophoretic 
mobility assays (EMSA) in polyacrylamide gel under non-denaturing 
conditions, and using 32P-labelled  oligonucleotides for radioactive 
detection. Gratifyingly, incubation of brC–Gu5 with the double- 
stranded oligo AP1hs•A/T, which contains the AP1 half-site required 
for peptide binging (TCAT) next to an A/T-rich site (AATTT), gave 
rise to a new slow-migrating band, consistent with the formation of a 
well-defined complex (Figure 2, panel A1). Moreover, EMSA titra- 
tions demonstrated the high stability of the resulting brC–Gu5 / 
AP1hs•A/T complex (KD ≈ 170 nM, see ESI). The brC–Gu4 analogue 
is also capable of forming discrete complexes with the composite 
target DNA, although in this case displaying much weaker binding 
(KD ≈ 813 nM, see ESI). It is important to note that the peptide brC 
itself binds the target DNA, under the same conditions, with a very 
low affinity (~10 µM).17 Importantly, additional experiments with 
oligos containing mutations in the A/T-rich site (AP1hs•mA/T, 
sequence: TCAT •  GGCCG), or  in the  peptide binding  site 
(mAP1hs•A/T,  sequence:  CGGC  •  AATTT),  showed  that  neither 
binding site in italics, and minor groove binding site underlined; 
only one strand shown). 
 
Circular dichroism is particularly suited to detect the interaction of 
bZIP peptides with DNA, because their binding is coupled to the 
folding of the basic region into an α-helix 19 Thus, incubation of a 5 
µM solution of brC–Gu5 with one equivalent of the oligonucleotide 
AP1hs•A/T resulted in a large increase of the negative band at 222 
nm, which correlates with the expected α-helix folding (Figure 3, 
left), and is in agreement with the high affinity displayed by this 
conjugate in the EMSA experiments. There is also an increase in the 
intensity of the negative band at 222 nm in the presence of the 
AP1hs•mA/T dsDNA , albeit lower than with AP1hs•A/T, while this 
increase is not observed with the DNA lacking the cognate peptide- 
binding site (mAP1hs•A/T) (see the ESI). Importantly, in addition to 
the folding of the peptide chain, CD experiments revealed a note- 
worthy distortion of the DNA upon formation of the complex with 
the brC–Gu5 conjugate, as evidenced by the changes in the charac- 
teristic bands of the B–DNA at 245 and 275 nm (Figure 3, left and 
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ESI). In contrast, the brC–R8 conjugate did not induce any change in 
the CD spectral region of the DNA, but there is folding of the pep- 
tide chain (Figure 3, right, and ESI). Interestingly, control CD exper- 
iments with the pentaguanidinium 3 also show a decrease in the 
intensity of the band at 275 nm (figure 3, left). All of these results 
suggest that the interaction of the guanidinium pentamer in brC– 
Gu5 with the DNA is intimate, and induces perturbations in the 
winding of the DNA helix, perhaps because of a shielding in the 




Fig 3. Circular dichroism of 5 µM solutions of brC–Gu5 and brC–R8 
in absence of DNA (dashed lines), and in the presence of 1 equiv of 
AP1hs•A/T (solid lines). The contribution of the parent DNA to the 
CD spectrum of the complexes has been subtracted. Samples con- 
tained 5 µM of corresponding dsDNA (when present) and 5 µM of 
peptides in 10 mM phosphate buffer (pH 7.5) and 100 mM of NaCl 
at 20 ºC. 
 
Taken together, these results indicate that the oligoguanidine hy- 
brids, particularly brC–Gu5, interacts efficiently with specific DNA 
sequences containing the AP1 half site (TCAT) adjacent to an A/T- 
rich region. The interaction is stronger and more selective than with 
the hybrid brC–R8, despite the fact that this conjugate contains more 
guanidinium groups. The high affinity and selectivity displayed by 
brC–Gu5 suggests that the rigid structure of the bicyclic guanidini- 
um scaffolds might be especially appropriate for complementing the 
DNA surface. While the preliminary molecular modeling suggested 
an interaction with the DNA phosphodiester backbone (Figure 1b), 
this would imply similar binding to different DNAs as long as they 
have the peptide-binding site. However, the experimental results 
indicate that AP1hs•A/T gives rise to more stable complexes than 
AP1hs•mA/T. Since it is known that many DNA binders interact 
with A/T-rich sites by inserting guanidinium or amidinium groups 
in the DNA minor groove,21 we hypothesized that the binding pref- 
erence of our conjugates for DNAs featuring A/T-rich tracts might 
result from the insertion of some of the guanidinium moieties into 
the minor grove of these sequences. 
Competition assays show that the water-soluble pentaguanidine 3 is 
capable of displacing a fluorescent bisbenzamidine probe from the 
A/T-rich minor groove of ds-oligos (see the ESI). 22 Not surprisingly, 
this displacement is highly dependent on the ionic strength of the 
medium, so that a low salt buffer containing 30 mM of NaCl induced 
the formation of more stable complexes (KD ≈ 9 nM), whereas in- 
creasing the concentration of NaCl to 100 mM results in a marked 
decrease in the affinity (KD ≈ 140 nM). These results suggest that the 
pentaguanidine  3  binds  to  dsDNAs  containing  A/T-rich  tracts 
through partial insertion of a number of bicyclic units in the minor 
groove and simultaneous formation of salt bridges between the 
terminal units and the phosphodiester backbone. This mechanism 
would account for the sequence selectivity observed with the conju- 
gate, as well as for the high influence of the ionic force. 
We finally carried out preliminary cell internalization  tests  using 
Vero cells and tetramethylrhodamine (TMR) derivatives of the 
GCN4 basic region, TMR–brC, and its  conjugates  TMR–brC–R8 
and TMR–brC–Gu5 (see the ESI). Thus, while TMR–brC is essen- 
tially not internalized (Figure 4A), the two conjugates led to a clear 
increase in the intracellular fluorescence (Figures 4B and 4C). The 
conjugates, which are not significantly cytotoxic (see the ESI), appear 
to be trapped in endocytic vesicles (Figures 4D-F). The future use of 
these compounds as genetic tools might require the incorporation of 
groups that could favor their endosomal escape and subsequent 
translocation into the nucleus. 23 
 
 
Fig 4. Fluorescence microscopy images of Vero cells incubated for 45 
min at 37 ºC. Top: Micrographs taken at 400X, ISO 400. (A) 5 μM of 
TMR–brC. (B) 5 μM of TMR–brC–R8. (C) 5 μM of TMR–brC–Gu5. 
Bottom: 5 μM of TMR–brC–Gu5 and co-staining with 2.5 μM of 
DAPI. at 1000X, ISO 400. (D) Red channel. (E) Blue channel. (F) 




In conclusion, tethering oligoguanidinium fragments to monomeric 
basic regions of a bZIP protein allows recovery of its interaction to a 
DNA consensus site, provided it is adjacent to A/T rich tracts. This 
A/T selectivity stems from the intrinsic preference of the oligoguani- 
dinium moiety to bind these sequences, most probably through 
insertion of some of its bicyclic units in the minor groove, while the 
others act as electrostatic phosphate clamps. The oligoguanidinium 
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